SL
VRTX icon

Salomon & Ludwin’s Vertex Pharmaceuticals VRTX Stock Holding History

Salomon & Ludwin’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.2K Buy
159
+38
+31% +$16.8K 0.01% 340
2026
Q1 		$53.1K Hold
121
– – ﹤0.01% 456
2025
Q4 		$54.3K Sell
121
-12
-9% -$5.17K ﹤0.01% 385
2025
Q3 		$53.6K Buy
133
+84
+171% +$35.1K ﹤0.01% 371
2025
Q2 		$22.4K Buy
+49
New +$22.6K ﹤0.01% 370
2024
Q2 		– Sell
-7
Closed -$2.93K – 833
2024
Q1 		$2.93K Hold
7
– – ﹤0.01% 697
2023
Q4 		$2.43K Hold
7
– – ﹤0.01% 643
2023
Q3 		$2.43K Buy
+7
New +$2.45K ﹤0.01% 641

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Salomon & Ludwin's VRTX Position: Q2 2026 in Review

Salomon & Ludwin increased its Vertex Pharmaceuticals (VRTX) stake by 31% in Q2 2026, buying an estimated $16.8K and bringing the position to 159 shares worth $79.2K. The position accounts for 0.01% of the portfolio, ranked #340.

Salomon & Ludwin first reported a position in VRTX in Q3 2023 and has held it in 8 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Salomon & Ludwin held 159 shares of Vertex Pharmaceuticals worth $79.2K as of Q2 2026.
  • Salomon & Ludwin bought 38 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.8K.
  • Vertex Pharmaceuticals made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #340 holding.
  • Salomon & Ludwin first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.